Correlation Between CytomX Therapeutics and NextCure

Can any of the company-specific risk be diversified away by investing in both CytomX Therapeutics and NextCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CytomX Therapeutics and NextCure into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CytomX Therapeutics and NextCure, you can compare the effects of market volatilities on CytomX Therapeutics and NextCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CytomX Therapeutics with a short position of NextCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of CytomX Therapeutics and NextCure.

Diversification Opportunities for CytomX Therapeutics and NextCure

0.48

Correlation Coefficient

CytomX Therapeutics  NextCure

Very weak diversification

The 3 months correlation between CytomX and NextCure is 0.48. Overlapping area represents the amount of risk that can be diversified away by holding CytomX Therapeutics and NextCure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCure and CytomX Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CytomX Therapeutics are associated (or correlated) with NextCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCure has no effect on the direction of CytomX Therapeutics i.e., CytomX Therapeutics and NextCure go up and down completely randomly.

Pair Corralation between CytomX Therapeutics and NextCure

Given the investment horizon of 90 days CytomX Therapeutics is expected to generate 0.99 times more return on investment than NextCure. However, CytomX Therapeutics is 1.01 times less risky than NextCure. It trades about 0.03 of its potential returns per unit of risk. NextCure is currently generating about -0.14 per unit of risk. If you would invest  101.00  in CytomX Therapeutics on August 29, 2024 and sell it today you would earn a total of  1.00  from holding CytomX Therapeutics or generate 0.99% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

CytomX Therapeutics  vs.  NextCure

CytomX Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

NextCure

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with CytomX Therapeutics and NextCure

The main advantage of trading using opposite CytomX Therapeutics and NextCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CytomX Therapeutics position performs unexpectedly, NextCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCure will offset losses from the drop in NextCure's long position.

The idea behind CytomX Therapeutics and NextCure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.